CN107405348B - Raf抑制剂与紫杉烷的组合 - Google Patents

Raf抑制剂与紫杉烷的组合 Download PDF

Info

Publication number
CN107405348B
CN107405348B CN201580073526.5A CN201580073526A CN107405348B CN 107405348 B CN107405348 B CN 107405348B CN 201580073526 A CN201580073526 A CN 201580073526A CN 107405348 B CN107405348 B CN 107405348B
Authority
CN
China
Prior art keywords
cancer
raf
compound
pharmaceutically acceptable
ras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580073526.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405348A (zh
Inventor
V·博泽恩
K·M·加尔文
R·L·布雷克
Q·徐
K·卡纳安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Point Therapy 1 Co
Original Assignee
Point Therapy 1 Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapy 1 Co filed Critical Point Therapy 1 Co
Publication of CN107405348A publication Critical patent/CN107405348A/zh
Application granted granted Critical
Publication of CN107405348B publication Critical patent/CN107405348B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580073526.5A 2014-12-23 2015-12-22 Raf抑制剂与紫杉烷的组合 Active CN107405348B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
US201562242629P 2015-10-16 2015-10-16
US62/242,629 2015-10-16
PCT/US2015/067462 WO2016106359A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and taxanes

Publications (2)

Publication Number Publication Date
CN107405348A CN107405348A (zh) 2017-11-28
CN107405348B true CN107405348B (zh) 2021-06-11

Family

ID=56151531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073526.5A Active CN107405348B (zh) 2014-12-23 2015-12-22 Raf抑制剂与紫杉烷的组合

Country Status (7)

Country Link
US (2) US20190117652A1 (enExample)
EP (1) EP3236966B1 (enExample)
JP (2) JP2018502087A (enExample)
CN (1) CN107405348B (enExample)
CA (1) CA2972189A1 (enExample)
ES (1) ES2827024T3 (enExample)
WO (1) WO2016106359A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. Solid dispersion of pan-raf kinase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300854A (zh) * 2008-12-02 2011-12-28 武田药品工业株式会社 作为抗癌剂的苯并噻唑衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
KR20110100241A (ko) * 2008-12-05 2011-09-09 아르퀼 인코포레이티드 Ｒａｆ 억제제 및 이들의 용도
RU2553379C2 (ru) * 2009-08-24 2015-06-10 Дженентек, Инк. ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA2904338C (en) * 2013-03-05 2022-07-05 University Of Tennessee Research Foundation Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300854A (zh) * 2008-12-02 2011-12-28 武田药品工业株式会社 作为抗癌剂的苯并噻唑衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies;U.S.National Library of Medicine;《http://clinicaltrials.gov/ct2/show/nct02327169》;20141230;第1-13页 *

Also Published As

Publication number Publication date
CA2972189A1 (en) 2016-06-30
ES2827024T3 (es) 2021-05-19
JP2020114857A (ja) 2020-07-30
EP3236966A4 (en) 2018-10-03
JP2018502087A (ja) 2018-01-25
EP3236966B1 (en) 2020-08-12
US20200316067A1 (en) 2020-10-08
WO2016106359A1 (en) 2016-06-30
EP3236966A1 (en) 2017-11-01
CN107405348A (zh) 2017-11-28
US20190117652A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
US20130231347A1 (en) Method of treatment with braf inhibitor
JP6254630B2 (ja) Ｒａｆ及びｍｅｋ阻害剤に対する耐性を与えるｍｅｋ１変異
JP6571105B2 (ja) 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
KR20230025941A (ko) 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
JP2024081710A (ja) ウイルス感染、炎症又は癌の処置におけるバイオマーカー及び使用
TW200908982A (en) Treatment of imatinib resistant leukemia
CN107205933A (zh) Raf抑制剂与aurora激酶抑制剂的组合
TW202021626A (zh) 辨識有可能受益於以端粒酶抑制劑治療之患者的方法
TW202039862A (zh) 受體酪氨酸激酶(kit)基因突變
KR20170070068A (ko) 레트 증후군의 치료
RS67265B1 (sr) Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c
CN107405348B (zh) Raf抑制剂与紫杉烷的组合
EP3589747B1 (en) Method of predicting effects of cdc7 inhibitor
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
HK40020609A (en) Method of predicting effects of cdc7 inhibitor
HK40020609B (en) Method of predicting effects of cdc7 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200324

Address after: California, USA

Applicant after: Point therapy-1 company

Address before: Massachusetts, USA

Applicant before: Millennium Pharmaceuticals, Inc.

GR01 Patent grant
GR01 Patent grant